Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor.
Terlizzi V, Fevola C, Presti S, Castaldo A, Daccò V, Claut L, Sepe A, Majo F, Casciaro R, Esposito I, Vitullo P, Salvi M, Troiani P, Ficili F, Parisi GF, Pantano S, Costa S, Leonetti G, Palladino N, Taccetti G, Bonomi P, Salvatore D.
Terlizzi V, et al. Among authors: bonomi p.
J Pediatr. 2024 Nov;274:114176. doi: 10.1016/j.jpeds.2024.114176. Epub 2024 Jun 28.
J Pediatr. 2024.
PMID: 38945446